Who are Quetiapine 600mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-08052666, mPnC candidate, Pf-08046045, PF-07321332 Dose 5, Isauvuconazole group, Talazoparib with enzalutamide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/quetiapine-600mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Quetiapine 600mg — Competitive Intelligence Brief

Quetiapine 600mg (Quetiapine 600mg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: atypical antipsychotic. Area: Neuroscience.

marketed atypical antipsychotic ["serotonin 5-HT2A receptors", "dopamine D2 receptors"] Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Quetiapine 600mg (Quetiapine 600mg) — AstraZeneca. Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Quetiapine 600mg TARGET	Quetiapine 600mg	AstraZeneca	marketed	atypical antipsychotic	["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
mPnC candidate	mpnc-candidate	Pfizer	marketed	Novel therapeutic agent	Specific protein or receptor involved in disease pathology	TBD
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Isauvuconazole group	isauvuconazole-group	Pfizer	marketed	Echinocandin	β-(1,3)-D-glucan synthase	Not yet launched
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (atypical antipsychotic class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
AstraZeneca · 2 drugs in this class
Eli Lilly and Company · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Sumitomo Pharma Co., Ltd. · 1 drug in this class
CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Quetiapine 600mg — Competitive Intelligence Brief. https://druglandscape.com/ci/quetiapine-600mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab